secwatch.observer — SEC 8-K summary
======================================

Issuer:     LIPELLA PHARMACEUTICALS INC. (LIPO)
CIK:        0001347242
Form:       8-K
Filed at:   2025-02-11T23:59:59+00:00
Accession:  0001753926-25-000211
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lipella reports positive Phase 2a results for LP-310 in oral lichen planus; FDA okays expanded access
--------------------------------------------------------------------------------

- FDA approved Expanded Access Program for LP-310 (oral rinse for OLP) on Feb 6, 2025.
- Phase 2a topline: statistically significant improvements in pain (NRS), IGA, REU, and OLPSSM at weeks 1, 4, 6.
- No product-related SAEs, no dropouts; tacrolimus blood levels undetectable or minimal in all patients.
- Trial advancing to 0.5 mg dose cohort; recruitment to conclude first half 2025.
- Company plans Phase 2b IND submission and Breakthrough Therapy request in second half 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1347242/000175392625000211/0001753926-25-000211-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1347242/000175392625000211/g084697_8-k.htm
  HTML page:      https://secwatch.observer/filing/0001753926-25-000211

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer